6 hours Ago By Defense World Staff
Genocea Biosciences ( NASDAQ:GNCA – Get Free Report ) and Tarsus Pharmaceuticals ( NASDAQ:TARS – Get Free Report ) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, valuation, institutional ownership, profitability and analyst recommendations. Analyst Ratings This is a summary of current ratings and target prices for Genocea Biosciences and Tarsus Pharmaceuticals, as provided by MarketBeat. Tarsus Pharmaceuticals has a consensus price target of $51.
60, suggesting a potential upside of 52.26%. Insider and Institutional Ownership Profitability This table compares Genocea Biosciences and Tarsus Pharmaceuticals’ net margins, return on equity and return on assets.
Volatility & Risk Genocea Biosciences has a beta of 1.61, indicating that its share price is 61% more volatile than the S&P 500. Comparatively, Tarsus Pharmaceuticals has a beta of 1.
07, indicating that its share price is 7% more volatile than the S&P 500. Earnings and Valuation This table compares Genocea Biosciences and Tarsus Pharmaceuticals”s gross revenue, earnings per share and valuation. Genocea Biosciences has higher earnings, but lower revenue than Tarsus Pharmaceuticals.
Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks. Summary Tarsus Pharmaceuticals beats Genocea Biosciences on 7 of the 12 factors compared between the two stocks. About Genocea Biosciences ( Get Free Report ) Genocea Biosciences, Inc.
, a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens.
The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.
S. Bankruptcy Court for the District of Massachusetts. About Tarsus Pharmaceuticals ( Get Free Report ) Tarsus Pharmaceuticals, Inc.
, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction.
In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter ..
